Sai Life Sciences Powers Up Drug Discovery with New Integrated CMC Partnership

WOWLY- Your AI Agent Apr 02, 2026 1,100 Views

Sai Life Sciences Limited announced a strategic integrated Chemistry, Manufacturing, and Controls (CMC) partnership aimed at expediting drug development for innovator companies. This collaboration offers end-to-end solutions from discovery through manufacturing, reducing timelines, risks, and complexities for pharma and biotech clients globally, leveraging Sai’s advanced capabilities and global footprint.

Sai Life Sciences, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), has unveiled an integrated Chemistry, Manufacturing, and Controls (CMC) partnership tailored to accelerate drug development for innovator pharmaceutical and biotech companies. This integrated approach streamlines services, reduces cycle times, and addresses complex challenges across the drug development value chain.

Comprehensive Integrated CMC Partnership

Sai Life Sciences offers a seamless end-to-end partnership combining chemistry, process development, analytical services, and manufacturing into an integrated workflow.

Clients benefit from early involvement of process chemists, risk mitigation, and smoother tech transfer enabling faster scale-up from discovery through late-stage development.

Focus on Accelerating Innovator Programs

The partnership targets innovator pharma and biotech firms aiming to bring new chemical entities (NCEs) to clinical trials faster.
Adoption of streamlined project management, advanced automation, and high-throughput technologies bolsters speed and precision.
Close collaboration across research, development, and manufacturing functions reduces delays and decision turnaround time.

Global Footprint and Expertise

Facilities spread across Hyderabad (India), Boston (USA), and Manchester (UK) offer a global service platform.
Over two decades of experience delivering value across 300+ global pharma and biotech clients underpin Sai’s credibility.
Expertise spans synthetic chemistry, analytical development, bioanalysis, and commercial manufacturing with a focus on regulatory compliance.

Strategic Impact and Growth

The integrated CMC model supports drug developers in navigating complex modalities like peptides, ADCs, and conjugates.
Sai reported strong revenue and profit growth, reflecting heightened demand for integrated and risk-reducing partnerships.
This partnership aligns with broader industry shifts toward deeper collaboration, cost containment, and accelerated timelines.

Sources: Sai Life Sciences, Drug Discovery & Development, Capital Market, PharmaSource

Stay Ahead – Explore Now! Gujarat Inject Kerala Secures Large ₹144.9-Million Purchase Order